CANTOS
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
- Stage
- klaar
- Medicine
- canakinumab
- Population
- ASCVD
- Phase
- III
- First Patient In
- 1 June 2011
- Last Patient In
- 1 March 2014
- Last Patient Last Visit
- 21 February 2019
National Lead
